Menu Search
Equities

Santen Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SNPHF:PKL

Santen Pharmaceutical Co Ltd

Actions
  • Price (USD)9.51
  • Today's Change0.00 / 0.00%
  • Shares traded400.00
  • 1 Year change--
  • Beta0.5588
Data delayed at least 15 minutes, as of Nov 25 2025 13:04 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Santen Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, and sale of pharmaceuticals. The Company engages in global research and development, manufacture, sale, and marketing of pharmaceuticals in the ophthalmology field. The Company engages in prescription pharmaceuticals, over-the-counter pharmaceuticals, medical devices, and other businesses. The Company operates in Japan, Asia, Europe, the Middle East, and Africa (EMEA), China, and other regions.

  • Revenue in JPY (TTM)287.99bn
  • Net income in JPY30.60bn
  • Incorporated1925
  • Employees3.85k
  • Location
    Santen Pharmaceutical Co Ltd3-9-19, Shimo-Shinjo, Higashiyodogawa-kuOSAKA-SHI 530-8552JapanJPN
  • Phone+81 676648621
  • Fax+81 663593827
  • Websitehttps://www.santen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.